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Abstract
Background Cachexia, a multifactorial syndrome affecting more than 50% of patients with advanced cancer and responsible
for ~20% of cancer-associated deaths, is still a poorly understood process without a standard cure available. Skeletal muscle
atrophy caused by systemic inflammation is a major clinical feature of cachexia, leading to weight loss, dampening patients’
quality of life, and reducing patients’ response to anticancer therapy. RAGE (receptor for advanced glycation end-products)
is a multiligand receptor of the immunoglobulin superfamily and a mediator of muscle regeneration, inflammation, and cancer.
Methods By using murine models consisting in the injection of colon 26 murine adenocarcinoma (C26-ADK) or Lewis lung
carcinoma (LLC) cells in BALB/c and C57BL/6 or Ager/ (RAGE-null) mice, respectively, we investigated the involvement of
RAGE signalling in the main features of cancer cachexia, including the inflammatory state. In vitro experiments were performed
using myotubes derived from C2C12 myoblasts or primary myoblasts isolated from C57BL/6 wild type and Ager/ mice
treated with the RAGE ligand, S100B (S100 calcium-binding protein B), TNF (tumor necrosis factor)α±IFN (interferon) γ, and
tumour cell- or masses-conditioned media to analyse hallmarks of muscle atrophy. Finally, muscles of wild type and Ager/
 mice were injected with TNFα/IFNγ or S100B in a tumour-free environment.
Results We demonstrate that RAGE is determinant to activate signalling pathways leading to muscle protein degradation in
the presence of proinflammatory cytokines and/or tumour-derived cachexia-inducing factors. We identify the RAGE ligand,
S100B, as a novel factor able to induce muscle atrophy per se via a p38 MAPK (p38 mitogen-activated protein
kinase)/myogenin axis and STAT3 (signal transducer and activator of transcription 3)-dependent MyoD (myoblast determina-
tion protein 1) degradation. Lastly, we found that in cancer conditions, an increase in serum levels of tumour-derived S100B
and HMGB1 (high mobility group box 1) occurs leading to chronic activation/overexpression of RAGE, which induces hallmarks
of cancer cachexia (i.e. muscle wasting, systemic inflammation, and release of tumour-derived pro-cachectic factors). Absence
of RAGE in mice translates into reduced serum levels of cachexia-inducing factors, delayed loss of muscle mass and strength,
reduced tumour progression, and increased survival.
Conclusions RAGE is a molecular determinant in inducing the hallmarks of cancer cachexia, and molecular targeting of RAGE
might represent a therapeutic strategy to prevent or counteract the cachectic syndrome.
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Introduction
Cachexia is a highly debilitating multifactorial syndrome
affecting more than 50% of patients with advanced cancer,
especially lung and upper-gastrointestinal cancer. Although
cachexia directly accounts for about 20% of all cancer-
associated deaths, it remains an underestimated and poorly
understood process, for which a complete pharmacological
cure is not available. The major clinical feature of cachexia
is skeletal muscle atrophy that leads to pronounced weight
loss, drastically dampened patients’ quality of life, reduced
response and tolerance to chemotherapy, and poor prognosis
and outcome.1,2
Systemic inflammation is thought to be a major mediator
of muscle wasting in individuals affected by cancer. Several
key cachexia-inducing factors have been shown to be
produced by host immune cells in response to the tumour
[e.g. interferon (IFN)γ, tumour necrosis factor (TNF)α, and
interleukin (IL)-6] or by the tumour cells themselves (e.g.
myostatin, activins, GDF15, TWEAK).2–4 These factors induce
a catabolic state in skeletal muscle principally caused by the
activation of the ubiquitin–proteasome system (UPS) and
autophagy–lysosome system (ALS), as well as a decrease of
protein synthesis.1,3 In cancer conditions, several pathways
[i.e. phosphatidylinositol (PI)-3-kinase/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR), p38
mitogen-activated protein kinase (MAPK), extracellular-sig-
nal-regulated kinases (ERK 1/2), and c-Jun N-terminal kinase
(JNK)] and transcription factors [such as signal transducer
and activator of transcription 3 (STAT3) and nuclear factor
kappa B (NF-κB)] are involved in the induction of the
muscle-specific ubiquitin ligases, atrogin-1 (muscle atrophy
F-box protein; Fbxo32) and muscle RING finger-1 (Trim63),
known as atrogenes, leading to proteolysis, especially of sar-
comeric myosin heavy chain (MyHC).5,6 Interestingly, reports
revealed an unexpected link between myogenin, an essential
transcription factor in the regulation of muscle differentia-
tion,7 and the maximal induction of atrogenes in several
non cancer conditions leading to muscle wasting.8,9
RAGE (receptor for advanced glycation end-products) is a
multiligand receptor of the immunoglobulin superfamily con-
sidered as a key mediator of several physiological and patho-
logical processes through the activation of multiple cellular
signalling cascades, depending on the cell type, environmen-
tal cues (i.e. the presence and concentration of RAGE li-
gands), and the density/activity of the receptor on the cell
surface.10–12 RAGE and its ligands, high mobility group box 1
(HMGB1) and the S100 calcium-binding protein B (S100B),
have been implicated in cell proliferation and survival, au-
tophagy, invasiveness, metastasis, and angiogenesis in sev-
eral cancer types.13–15 S100B is normally present in human
serum, and its serum levels are elevated in some human tu-
mours, representing a prognostic marker in patients with cu-
taneous melanoma and breast cancer.6 Moreover, by
interacting with the ‘alarmins’ HMGB1 and S100B, RAGE par-
ticipates in innate and adaptive immune responses, immune
cell migration and chemotaxis, and cytokines production.11
We have identified RAGE, S100B, and HMGB1 as physio-
logical regulators of myogenesis and muscle regeneration
upon acute muscle injury via p38 MAPK-dependent induc-
tion of myogenin.12,16–18 However, the continuous release
of high S100B and HMGB1 by damaged myofibres and infil-
trating macrophages as found in muscular dystrophy fuels
inflammation and dampens the reparative process,17,19 and
overstimulation of RAGE leads to muscle wasting and
altered muscle metabolism in ageing and pathological condi-
tions such as diabetes, obesity, and myopathies.12,20 Yet,
the possible role of RAGE and its ligands, in particular
S100B, in cancer-induced muscle wasting has not been
investigated so far. Herein, we show that (i) inflammatory
cytokines and cachexia-inducing factors (including S100B
and HMGB1) induce RAGE expression in skeletal muscles;
and (ii) RAGE hyperactivation plays a relevant role in the
loss of muscle mass in cancer conditions principally via a
p38 MAPK/myogenin/atrogin-1 axis. We propose that RAGE
is an important molecular determinant of muscle atrophy in
cancer patients and a potential therapeutic target.
Methods
Cell cultures
Murine C2C12 myoblasts were grown in high-glucose
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 20% foetal bovine serum (FBS), 100 U/ml penicillin and
100 mg/ml streptomycin (P/S) (growth medium, GM).
Differentiation into myotubes was induced by shifting sub-
confluent myoblasts to DMEM supplemented with 2% horse
serum (HS) (differentiation medium, DM) for 4 days. Primary
myocytes were obtained as described.16
Myotubes were treated with TNFα (20 ng/ml) ± IFNγ
(100 U/ml), S100B (0–20 μg/ml), or HMGB1 (0–30 μg/ml)
for the indicated time. In parallel experiments, myotubes
were pre-treated for 30 min with anti-RAGE blocking
antibody (0-50 μg/ml), a neutralizing anti-S100B antibody
(2 μg/ml), glycyrrhizin (50 μM) or the chemical inhibitors,
SB 203580 (inhibitor of p38 MAPK; 10 μM) or BAY 11-7082
(inhibitor of NF-κB; 10 μM).
Lewis lung carcinoma (LLC) and colon 26 murine adenocar-
cinoma (C26-ADK) cells were cultured in high-glucose DMEM
or Roswell Park Memorial Institute (RPMI) 1640, respectively,
containing P/S and supplemented with 10% FBS (GM). C2C12,
LLC, and C26 cells were maintained in a humidified atmo-
sphere containing 5% CO2 at 37 °C. To obtain conditioned
media (CM), once the plates reached a > 90% confluence,
GM was removed, and cells were washed twice with sterile
2 S. Chiappalupi et al.
Journal of Cachexia, Sarcopenia and Muscle 2020
DOI: 10.1002/jcsm.12561
phosphate-buffered saline (PBS) and incubated in serum-free
DMEM with P/S. After 24 h, the medium was collected and
centrifuged in 50ml tubes at 4500 r.p.m for 15min at 4°C. Al-
iquots of the cell-cleared medium were stored at 80°C. To
obtain tumour-conditioned medium (TM), LLC and C26
masses were dissected and placed in sterile PBS. The tumour
was minced into parts of approximately 2mm3, washed twice
with PBS and incubated in serum-free DMEM containing P/S.
TM was collected after a 48 h incubation. C2C12 myotubes
were treated with CM or TM added to a differentiation me-
dium (25% v/v) for the indicated time.
Animal models
Ten-week-old mice were injected subcutaneously (s.c.) in the
hind flank with LLC cells (1.0 × 106 cells/mouse) in the case of
C57BL/6 wild type (WT) and Ager/ mice or with C26 cells
(0.5 × 106 cells/mouse) in the case of BALB/c mice. Tumours
were allowed to develop for different time-points, compared
with PBS-injected control mice. Body weight was measured
every 3 days starting from tumour appearance and calculated
by subtracting tumour weight from total weight. Tumour
measurements were taken using a digital calliper (Exacta
Optech) and tumour volumes calculated with the formula,
(length × width2)/2. At the indicated time, animals were
sacrificed and sera were collected. Skeletal muscles, adipose
tissue, lungs, spleens, and tumours were surgically excised
and weighed. In any case, mice were sacrificed if human-
end points were reached. The occurrence and numbers of
lung metastases were measured.
Gastrocnemius (GC) muscles of WT and Ager/mice were
injected with PBS, or TNF-α (3 μg/muscle) plus IFNγ (5000 U/
muscle) or S100B (50 ng/muscle) for three consecutive days.
To obtain CM, muscles were incubated in PBS for 1 h at 4°C.
Treatments of animals were performed under zolazepam/
tiletamine or isofluorane anaesthesia. Animal procedures
followed the 3Rs principles in alignment with the Directive
2010/63/EU of the European Union and approved by the
Ethics Committee of Perugia University and Italian Ministry
of Health. Mice were housed under specific pathogen-free
conditions on a 12 h light/day cycle, and raised under a stan-
dard mouse diet.
Kondziela’s inverted screen test
Each mouse was placed in the centre of a wire mesh screen,
the screen was rotated by 180°, and the time when the
mouse fell off was measured for a maximum of 8 min. Each
mouse was evaluated in three trials at 10 min inter-trial
intervals.
Real-time polymerase chain reaction (real-time
PCR)
Total RNA was extracted from cell cultures or skeletal muscle
homogenates using a commercial TRIsure™ reagent following
the manufacturer’s instructions. Reverse-transcription was
obtained using a PrimeScript™ RT reagent kit. Real-time PCR
analyses of messenger RNA (mRNA) contents were per-
formed on Stratagene Mx3000P (Agilent Technologies, CA,
USA) using 5×HOT FIREPol EvaGreen qPCR Mix Plus (ROX)
ready-to-use solution. Calculation was performed with a spe-
cific software in comparison with a standard gene (Gapdh).
The primers used for real-time PCR analysis are reported in
Table S2 (Supplemental Material).
Western blot (WB)
Myotube cultures, skeletal muscle or tumour masses homog-
enates were lysed in protein extraction buffer containing
10 mM Tris–HCl (pH 7.4), 2.5% v/v sodium dodecyl sulfate,
100 mM dithiothreitol, and 200 mM phenylmethanesulfonyl
fluorid, 10 mg/ml aprotinin, 1 mg/ml pepstatin, and
5 mg/ml leupeptin, all from Sigma Aldrich. Equal amounts
of total protein extract were resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and transferred
to nitrocellulose blots (Amersham™ Protran™, 0.45 μm). Fol-
lowing blocking with 5% non-fat dried milk primary and sec-
ondary antibodies were applied as indicated in Table S3
(Supplemental Material). For S100B detection, blots were
blocked with 5% bovine serum albumin (BSA). The immune
reactions were developed by enhanced chemiluminescence.
C-DiGit Blot Scanner (LI-COR, NE, USA) was used for blot
analysis.
Immunocytochemistry (ICC) and
immunofluorescence (IF)
Myotubes were washed with Tris-buffered saline (TBS), fixed
for 7 min with cold absolute methanol and permeabilized for
10 min with 0.1% Triton X-100 in TBS solution, blocked with
blocking buffer (10% HS and 0.1% Triton X-100 in TBS) for
1 h, and incubated overnight at 4°C with mouse anti-MyHC-
II primary antibody (1:1000 in 10% HS). Myotubes were
washed, incubated with appropriate secondary biotinilated-
antibody, rinsed with TBS containing 0.01% Tween-20
(T-TBS), and then incubated for 45 min with Vectastain ABC
reagents. After washing with TBS, myotubes were incubated
with 0.01% 3, 3-diaminobenzidine tetrahydrochloride, Nichel,
and 0.006% H2O2 in 50 mM Tris–HCl (pH 7.4) for 8 min. The
reaction was blocked with 50 mM Tris–HCl. Mounting me-
dium (Dako Corporation) was added, and pictures were taken
using a bright field microscope (Olympus BX51) equipped
with a digital camera.
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For IF staining, myotubes cultivated on sterile glass cover-
slips were fixed with 4% paraformaldehyde, permeabilized
using 0.1% Triton X-100 in PBS, blocked with blocking buffer
containing 1% glycine and 3% BSA in PBS, and incubated in
a humid chamber overnight at 4 °C with mouse anti-MyHC-
II or rabbit anti-pho-STAT3 primary antibody in PBS contain-
ing 3% BSA (Table S4 in Supplemental Material). The next
day, coverslips were incubated with appropriate Alexa Fluor
488-conjugated antibody in PBS containing 3% BSA (Table
S4 in Supplemental Material), in a light-tight humid chamber,
and counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) to visualize the nuclei. At the end, coverslips were
mounted with fluorescent mounting medium containing
80% glycerol and 20% PBS and viewed by an epifluorescence
microscope (Leica DMRB) equipped with a digital camera.
Evaluation of myotube diameter
Myotube diameters were determined on images of MyHC-II
staining at 20× magnification using ImageJ software. Three
different measurements were performed along the longitudi-
nal axis of each myotube. Average diameters of at least 100
myotubes from 10 randomly chosen fields for each condition
were determined. Results were expressed as percentages
with respect to control myotubes.
Analysis of conditioned media
CM or TM were added with 1/100 volume of 2% sodium
deoxycholate (Sigma Aldrich) and subjected to precipitation
with 1/10 volume of 100% trichloroacetic acid (Sigma
Aldrich). The resultant pellets were resuspended in Laemmli
buffer and titrated with 1 N NaOH to obtain the normal blue
colour of the sample buffer, boiled for 5 min, and subjected
to western blotting to analyse the expression of S100B or
HMGB1 (Table S3 in Supplemental Material).
Histology, immunohistochemistry (IHC), and IF
Muscles, spleens, lungs, and tumour masses were isolated,
formalin-fixed, and paraffin-embedded in order to maximally
preserve morphology. Muscle cross-sections measuring 4 μm
were obtained and processed for standard haematoxylin/
eosin staining. Tumour masses were processed for Masson’s
trichrome staining (Sigma-Aldrich) to evaluate fibrosis. Slices
were analysed and photographed with a bright field micro-
scope (Olympus BX51) equipped with a digital camera.
Myofiber cross-sectional areas (CSAs) and tumour necrosis
areas were measured using ImageJ software on total sections
at 100 μm intervals for each muscle or tumour mass.
Paraffin sections were deparaffinized with xylene and
rehydrated in a graded ethanol series. Antigen retrieval
was performed by boiling for 1.5 h in 10 mM citric acid
buffer (pH 6.0), and depletion of endogenous peroxidase
was accomplished by treatment with 3% H2O2. The sections
were probed with anti-RAGE primary antibody diluted 1:50
in B.B. (T-TBS and 10% HS) and the sections incubated
overnight in a humid chamber at 4°C. After several wash-
ings in T-TBS, the sections were incubated with anti-goat
biotinylated antibody (1:500 dilution) for 1 h in B.B. The
sections were rinsed in T-TBS, incubated for 45 min with
Vectastain ABC reagents, washed again in TBS, and incu-
bated with 0.01% 3-diaminobenzidine tetrahydrochloride
(DAB), 0.006% H2O2 in 50 mM Tris–HCl (pH 7.4). Nuclei
were counterstained with haematoxylin. The sections were
dehydrated and mounted with EuKitt mounting medium
(Electron Microscopy Sciences). Slices were photographed
in a bright field microscope (Olympus BX51) equipped with
a digital camera.
To perform double IF , after cooling, slices were washed
in PBS incubated for 30 min in 1% H2O2 in methanol in the
dark to inactivate endogenous peroxidase, blocked for 1 h
at room temperature with B.B. (1% BSA, 0.4% Triton
X-100, 10% HS), and incubated in a humid chamber over-
night at 4°C with the primary antibodies (Table S4 in Sup-
plemental Material) diluted in 1% BSA and 0.4% Triton X-
100 in PBS. The next day, slices were washed in Triton X-
100 in PBS and incubated with the specific Alexa Fluor-
conjugated antibodies (Table S4 in Supplemental Material)
diluted 1:100 in 0.1% BSA in PBS. To reduce autofluores-
cence, the sections were additionally stained with 0.3%
Sudan Black B (Sigma Aldrich) in 70% ethanol for 10 min
in the dark. For RAGE and MAC3, double immunofluores-
cence slices were blocked with 3% BSA and 1% glycine in
PBS, and primary and secondary antibodies diluted in 3%
BSA in PBS. Nuclei were counterstained with DAPI. After
rinsing, sections were mounted with anti-fading mounting
medium (Dako Corporation, Denmark) and viewed in an
epifluorescence microscope (Leica DMRB) equipped with a
digital camera.
Enzyme-linked immunosorbent assay (ELISA) and
multiplex cytokine assay
Blood samples were collected after mice terminal decapita-
tion, and serum was collected. Serum cytokine levels were
measured using a ProTM Mouse Cytokine 23-plex Assay kit
according to the manufacturer’s instructions and analysed
by a MAGPIX® Multiplexing Instrument (Luminex Corpora-
tion). Serum S100B and HMGB1 levels were measured using
a mouse-specific ELISA assay kits according to the manufac-
turers’ protocol.
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Reagents and resources
See Supporting Information Table S1.
Statistical analysis
Quantitative data are presented as means ± standard error
(SEM) of the mean or standard deviation (SD) of at least three
independent experiments. The number of animals used is
specified in each experiment. Counts were performed by
three independent operators blind to the treatments. Repre-
sentative experiments and images are shown unless stated
otherwise. Statistical analysis was performed using two-
tailed, unpaired t-test for single variables and two-way analy-
sis of variance followed by Dunnet test for multiple variables.
A Mann–Whitney test was used for statistical analysis of lung
metastasis numbers. P values lower than 0.05 were consid-
ered statistically significant. All statistical data were proc-
essed by IBM® SPSS® Statistics Version 18 software.
Results
Tumour presence causes re-expression of RAGE in
muscle tissue and increases serum levels of the
RAGE ligands, S100B, and HMGB1
RAGE is absent in healthy adult myofibers and quiescent mus-
cle stem cells (i.e. satellite cells; SCs). However, RAGE is
expressed during skeletal muscle development, and it is tran-
siently re-expressed in activated/proliferating SCs, differenti-
ating myoblasts and regenerating myofibers upon muscle
injury.16,21 Re-expression of RAGE in adult myofibers occurs
also in certain myopathies.12
We analysed RAGE expression over time in tibialis anterior
(TA), GC, and quadriceps femoris (QF) muscles of C57BL/6
mice injected s.c. with LLC cancer cells (LLC-WT), as one of
the best-characterized experimental models of cancer ca-
chexia.22 At Day 25 post-injection (dpi), LLC-WT mice had lost
~25% body (Figure 1A), ~70% fat (Figure 1B), and ~34% TA,
~15% GC, and ~15% QF (Figure 1C) muscle weight compared
with untreated mice, indicating a cancer-induced cachectic
condition. These same parameters were found unchanged
at 15 dpi in LLC-WT mice (Figure 1A–C). Similarly, the analysis
of myofiber size distribution in TA muscles showed a 30% av-
erage reduction of CSA in LLC-WT compared with untreated
mice at 25 dpi (Figure 1D and Figure S1A), whereas LLC-WT
CSA was unchanged at 15 dpi. Interestingly, TA, GC, and QF
muscles of cachectic mice showed increased levels of the
RAGE gene (Ager) already at 15 dpi (Figure 1E) and Ager up-
regulation increased in muscles during muscle wasting pro-
gression (Figure 1E). The re-expression of RAGE at 15 and
25 dpi in TA muscles of LLC-WT mice was confirmed by WB
and IHC analysis, respectively (Figure 1F,G). By double IF
staining RAGE was detected in atrogin-1-positive (atrogin-
1+ve) (i.e. atrophic) TA myofibers of LLC-WT mice at 25 dpi
(Figure 1H).
Serum levels of the RAGE ligands, S100B, and HMGB1 also
were robustly increased in LLC-bearing compared with
untreated mice (Figure 1I), likely released from tumour cells.
Indeed, conditioned medium derived from LLC cells (LLC-CM)
or LLC tumour masses (LLC-TM) contained significant
amounts of S100B and HMGB1 (Figure 1J). Similar results
were obtained in C26-bearing BALB/c mice (Figure S1B–E).
Thus, RAGE re-expression in muscles of LLC-bearing mice
precedes the reduction of myofiber CSA and the loss of
muscle, body, and fat mass, and RAGE overexpression is con-
comitant with increased serum levels of S100B and HMGB1
released by tumour cells, suggesting a role for RAGE signalling
in the development of cancer cachexia.
Absence of RAGE prevents cancer-induced cachexia
and prolongs survival of Lewis lung carcinoma
tumour-bearing mice
To determine the role of RAGE in skeletal muscle in cancer
cachexia, we used the RAGE-null (Ager/) mice (C57BL/6
background).23 WT and Ager/ mice inoculated s.c. with
LLC cells showed a similar increase in tumour size (Figure
2A). Histological analysis of LLC masses derived from LLC-
WT or LLC-Ager/ mice showed that the absence of RAGE
did not affect the extent of necrotic and fibrotic (extremely
low) areas in LLC masses (Figure S2A,B) at 15 and 25 dpi.
Thus, similar if not identical numbers of actively growing
cancer cells were potentially able to induce cachexia in both
mouse models.
Interestingly, LLC-WT and LLC-Ager/ mice showed a
different loss of body weight over time (Figure 2B). LLC-WT
mice showed significantly decreased body weight (~13%) at
22 dpi with maximum decrease (~36%) at 37 dpi, whereas
LLC-Ager/ mice significantly lost body weight starting from
30 dpi (~24%), with a ~30 and ~37% weight loss at 37 and 40
dpi, respectively (Figure 2B). Noteworthy, LLC-Ager/ mice
showed a surprisingly higher survival rate compared with
LLC-WT mice, with ~80% alive LLC-Ager/ mice vs. no
surviving LLC-WT mice at 40 dpi (Figure 2C). Specifically,
60% LLC-WT mice were found dead at 25 dpi, whereas all
LLC-Ager/ mice survived until 28 dpi (Figure 2C).
LLC-Ager/ survivors at 40 dpi were sacrificed having
reached ethically determined end points. Thus, absence of
RAGE delays the loss of body weight and remarkably prolongs
lifespan of tumour-bearing mice, without affecting tumour
growth.
Since RAGE has been implicated in the occurrence of lung
metastases,24 which strongly reduce the survival of LLC-
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Figure 1 Tumour presence causes a re-expression of receptor for advanced glycation end-products (RAGE) in muscle tissue and increases serum levels
of the RAGE ligands, S100 calcium-binding protein B (S100B) and high mobility group box 1 (HMGB1). (A–I) C57BL/6 wilde-type (WT) mice injected with
Lewis lung carcinoma (LLC-WT) cells or vehicle (Ctrl-WT) (n = 8 each group) were sacrificed at the indicated day post-injection (dpi). The weights of
body (A), fat (i.e. inguinal white adipose tissue, iWAT and epididymal white adipose tissue, eWAT) (B), and tibialis anterior (TA), gastrocnemius (GC)
and quadriceps femoris (QF) muscles (C) were measured. (D) Reported is the average of percentage changes of TA myofiber cross-sectional area
(CSA) for LLC-bearing mice compared with control mice (see also Figure S1A). Skeletal muscles were analysed for RAGE expression by real-time PCR
(E), western blot (WB) (F), and immunohistochemistry (IHC) (G). (H) RAGE (red) was detected by immunoflourescence (IF) in atrophic myofibers marked
with atrogin-1 (green). 4′,6-diamidino-2-phenylindole (DAPI) (blue) was used to stain nuclei. Dashed lines indicated myofiber borders. (I) Serum levels of
S100B and HMGB1 were measured by enzyme-linked immunosorbent assay (ELISA). (J) S100B and HMGB1 were detected in LLC cell lysates, condi-
tioned medium derived from LLC cells (LLC-CM), and LLC tumour masses (LLC-TM) by WB. M, purified S100B (5 ng), or HMGB1 (10 ng). Results are
means ± standard error of the mean. Statistical analysis was conducted using the two-tailed t-test. *P < 0.05, **P < 0.01, and ***P < 0.001 significantly
different from control mice.
#
P<0.05,
##
P<0.01 significantly different. Scale bars (G,H), 50 μm.
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Figure 2 Depletion of receptor for advanced glycation end-products (RAGE) prevents cancer-induced cachexia, prolongs survival and maintains spleen
morphology in Lewis lung carcinoma (LLC) tumour-bearing mice. (A–I) Wild type (WT) and Ager/ mice (n = 15 each group) injected with LLC cells
were monitored for tumour growth (A), changes in body weight (B), and survival rates (C) until 40 dpi and sacrificed at the indicated dpi. (D) The num-
ber of lung metastases/mouse was determined (see also Figure S2C) over time in LLC-WT and LLC-Ager/mice (n = 8 each group). (E) Skeletal muscles
were excised and weighed. (F) Reported is the average of percentage changes of tibialis anterior (TA) of the cross-sectional area (CSA) for each mouse
model compared to control WT mice (see also Figure S3A,B). (G) Plotted are the means ± standard error of the mean (SEM) of time latencies to fall in
Kondziela’s inverted screen test, in which each point represents an individual mouse. Spleens were weighed (H), and spleen morphology was analysed
by haematoxylin/eosin (H&E) staining (I). Dashed lines indicate the boundaries of white and red pulps. Results are means ± SEM (A–F). Statistical anal-
ysis was conducted using the two-tailed t-test (A,B,E–H) or Mann–Whitney test (D). Significance (P) is indicated for each time-point starting from 22 dpi
(B).
*
P < 0.05,
**
P < 0.01, and *** P<0.001, significantly different from internal control mice (D,E,G,H).
$
P < 0.05 and
$$
P < 0.01, significantly (D).
§P < 0.05 and §§P < 0.01, significantly different from WT (F). #P < 0.05, ## P<0.01, and ###P < 0.001 significantly different. Scale bars in (I), 200 μm.
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bearing mice, we investigated the occurrence and number of
metastases in LLC-Ager/ mice vs. LLC-WT mice over time.
We found no lung metastases at 15 dpi in LLC-WT or LLC-
Ager/ mice (Figure 2D and Figure S2C). At 25 dpi, the oc-
currence and the number of lung metastases in LLC-Ager/
mice were lower than in WT mice (37.5% vs. 83.3%, and
0.37 ± 0.2 vs. 1.33 ± 0.4, respectively in LLC-Ager/ vs.
LLC-WT mice) (Figure 2D and Figure S2C). However, at 40
dpi, 100% of survivor LLC-Ager/ mice showed a large num-
ber (11.66 ± 5.7/mouse) of lung metastases (Figure 2D and
Figure S2C). Thus, the reduced presence of metastases might
only contribute to increase the survival rate of LLC-Ager/
mice at 25 dpi.
Since cachexia is in large part caused by a decrease in skel-
etal muscle mass2,3 we weighed TA, GC, and QF muscles. At
25 dpi, muscles of LLC-WT but not LLC-Ager/ mice weighed
significantly less than those of untreated internal controls
(Figure 2E), suggesting that absence of RAGE confers protec-
tion against cancer-induced muscle wasting during the first
25 dpi. However, at 40 dpi, a ~50% weight decrease was ob-
served in muscles of survivor LLC-Ager/ mice (Figure 2E).
Analysis of myofiber size distribution in TA muscles at 25
dpi showed unchanged average CSA in LLC-Ager/ mice
compared with their untreated control as opposed to LLC-
WT mice, which showed a 33.3% average reduction of CSA
compared with their untreated control (Figure 2F). However,
a significant prevalence of thin myofibers responsible for a
27.9% average reduction of CSA was detected in LLC-Ager/
 mice at 40 dpi (Figure 2F and Figure S3A,B). Accordingly,
LLC-Ager/ mice showed a significantly higher muscle
strength compared with LLC-WT mice at 25 dpi in Kondziela’s
inverted screen test (Figure 2G). Notably, the average CSA
detected in TA muscles of control Ager/ mice was signifi-
cantly higher than in control WT mice (Figure 2F and Figure
S3A,B), in agreement with the reported high basal number
of large (>3500 μm2) myofibers in Ager/ muscles.16
Serum cytokine profiling revealed increased levels of all the
factors investigated with the exception of IL-1α in LLC-WT
mice at 25 dpi compared with untreated controls (Table 1
and Figure S4). At this time point, LLC-Ager/ mice showed
a serum protein pattern compatible with a reduced inflam-
matory state, as revealed by the significantly lower levels of
IL-3, IL-6, IL-9, IL-12p40, IL-12p70, and IL-17A, IFNγ, and
TNFα, and higher levels of IL-1β compared with LLC-WT. In-
terestingly, in LLC-Ager/ survivors at 40 dpi, the serum
levels of IL-3 and IL-12p40, IFNγ, and TNFα remained even
lower than those of LLC-WT mice at 25 dpi (Table 1 and Fig-
ure S4), indicative of the perpetuation of the low inflamma-
tory state in LLC-Ager/mice. The low level of the anti-
inflammatory cytokine, IL-10, in LLC-Ager/ at 40 dpi might
be a mirror and the consequence of a reduced inflammatory
state.
Increased spleen size (splenomegaly) and disruption of
spleen structure caused by dramatic expansion of immune
cells is typically observed in experimental cancer.4,25 LLC-
WT, but not LLC-Ager/ mice, showed splenomegaly with
a ~180% spleen weight increase compared with untreated
controls at 15 dpi; however, a ~500% spleen weight increase
was registered at 25 dpi in both LLC-WT and LLC-Ager/
mice (Figure 2H). At 15 and 25 dpi, spleens of LLC-WT mice
showed disappeared boundaries of white and red pulps, with
expanded haematopoietic red pulp (Figure 2I), a hallmark of
systemic inflammation. In contrast, at 15 and 25 dpi, LLC-
Ager/ mice showed a normal spleen morphology, which
was partially conserved even at 40 dpi (Figure 2I). Collec-
tively, these data suggested that RAGE sustains the inflamma-
tory response in tumour conditions increasing the serum
levels of cytokines involved in the development of cancer ca-
chexia and that absence of RAGE delays the occurrence of
lung metastases, delays loss of body and muscle mass, and
prolongs survival of tumour-bearing mice.
RAGE activity is critical for LLC-induced muscle
wasting
At 25 dpi, GC and TA muscles of LLC-WT showed strongly re-
duced levels of MyoD and the major sarcomeric protein,
MyHC-II, compared with untreated mice (Figure 3A and Fig-
ure S5A). Muscles of LLC-Ager/ showed slightly decreased
MyoD and increased MyHC-II levels at 25 and 40 dpi, indicat-
ing that absence of RAGE translates into resistance against
muscle protein degradation. However, muscles of untreated
Ager/ mice showed remarkably higher amounts of the
slow isoform MyHC-I compared with WT muscles, and in
LLC-Ager/ muscles, a robust degradation of MyHC-I
occurred at 25 and/or 40 dpi (Figure 3A and Figure S5A,B).
Table 1 Serum cytokine multiplex analysis.
Analyte
Sample
Fold change
(%), LLC-WT
25 dpi vs.
Ctrl-WT
Fold change
(%), LLC-Ager/
25 dpi vs.
Ctrl-Ager/
Fold change
(%), LLC-Ager/
40 dpi vs.
Ctrl-Ager/
IL-1a 0.00 30.7 22.9
IL-1b 249.4 ↑942.2* ↑7505.4**
IL-3 155 106.7 ↓13561.8** ↓33 691.9**
IL-6 10 072.2 ↓3576.2* ↑21 109.5*
IL-9 166 853.3 ↓13561.8** 163 480
IL-10 26 875.5 15622.5 ↓1983*
IL-12p40 44 174.9 ↓200.3** ↓117.1**
IL-12p70 416 460 ↓111627.5* 462 033
IL-17A 38 200 ↓8110* 58 040
IFNγ 243 863.3 ↓778.1** ↓9983.5**
TNFα 20 646.6 ↓394.2* ↓3477.5*
Sera of LLC-WT and LLC-Ager/mice were analysed for the expres-
sion of cytokines by Biorad Bio-Plex multiplex array compared with
internal controls. Statistical analysis was conducted using the anal-
ysis of variance, Dunnet test.
IFN, interferon; IL, interleukin; TNF, tumour necrosis factor.
*P < 0.05 and
**P < 0.01, significantly different from LLC-WT mice.
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Figure 3 Receptor for advanced glycation end-products (RAGE) activity is critical for Lewis lung carcinoma (LLC)-induced muscle wasting. (A–D) Gas-
trocnemius muscles from LLC-wild type (WT) and LLC-Ager/ mice were analysed compared with internal control mice (Ctrl) at the indicated dpi. (A)
myoblast determination protein 1 (MyoD), myogenin and the adult fast [myosin heavy chain (MyHC)-II] and slow (MyHC-I) myosin heavy chain isoforms
were detected by western blot (WB). Reported are the relative densities. (B) Expression of developmental MyHC (dMyHC) at 25 dpi was analysed by
western blot (WB). α-Actinin or GAPDH were used for loading control (A,B). (C) Levels of Fbxo32, Trim63 andMyog were analysed by real-time PCR. (D)
Myogenin (red) and atrogin-1 (green) were detected by immunofluorescence (IF). 4′,6-diamidino-2-phenylindole (DAPI) (blue) was used to stain nuclei.
See also Figure S5. Reported are high-magnification insets with myofibers defined by dashed lines. Results are means ± standard error of the mean.
Statistical analysis was conducted using the two-tailed t-test.
*
P < 0.05,
**
P< 0.01, and *** P<0.001, significantly different from internal control mice.
#P < 0.05, ##P < 0.01 and ###P < 0.001 significantly different. $P < 0.05 and $$P < 0.01 LLC-Ager/ vs. LLC-WT mice significantly different (C). Scale
bars in (D), 25 μm.
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Similarly, higher amounts of the developmental isoform,
dMyHC, were found in muscles of untreated Ager/ mice,
and dMyHC appeared degraded in LLC-Ager/, but not in
LLC-WT mice, at 25 dpi (Figure 3B). At 15 and 25 dpi, levels
of the atrogenes, Fbxo32 (atrogin-1) and Trim63 (MuRF1),
were significantly increased in muscles of LLC-WT mice, as ex-
pected, whereas they were unchanged or only slightly in-
creased in LLC-Ager/ muscles at 15 and 25 dpi,
respectively, compared with their untreated controls
(Figure 3C and Figure S5C). At 40 dpi, atrogenes in survivor
LLC-Ager/ muscles reached levels comparable to those
found in LLC-WT muscles at 25 dpi. Interestingly, mRNA,
and protein levels of myogenin, which has been demon-
strated to induce Fbxo32 and Trim63 in different non cancer
atrophying conditions,8,9,26 increased in LLC-WT muscles al-
ready at 15 dpi and even more so at 25 dpi (Figure 3A,C
and Figure S5A,C,D). Myogenin was detected in myonuclei
of atrophying (atrogin+ve) myofibers (Figure 3D), as confirmed
by double-IF analysis using dystrophin as a marker of the sar-
colemma (Figure S5E). We exclude that myogenin+ve nuclei
observed in myofibers of cachectic mice derive from muscle
precursor cells because in cachexia conditions activated mus-
cle precursor cells are unable to terminally differentiate (and
to express myogenin) and fuse into myofibers.27,28
Notably, no such changes in myogenin expression occurred
in LLC-Ager/ muscles until 40 dpi (Figure 3A,C,D and Figure
S5A,C). Collectively, these results suggest that tumour-
induced re-expression of RAGE in skeletal muscles is concom-
itant with the activation of UPS and the up-regulation of
myogenin and that RAGE signalling is critical for muscle pro-
tein degradation.
RAGE signalling is required for TNFα ± IFNγ-induced
muscle atrophy
To investigate the molecular mechanism(s) underpinning the
atrophying activity of muscular RAGE in cancer condition, we
used two well-characterized in vitro models of muscle atro-
phy consisting of myotube cultures exposed to TNFα alone
or in combination with IFNγ. TNFα ± IFNγ is known to cause
a pronounced and selective reduction of sarcomeric MyHC-
II by different and still poorly understood mechanisms.29,30
TNFα alone induces MyHC degradation principally through
the activation of UPS by enhancing atrogenes expression via
p38 MAPK and/or by MyoD degradation via NF-κB.30,31
Myogenin is required for maximal activation of atrogenes in
the presence of TNFα,9 whereas the combination of
TNFα/IFNγ induces reduction of myotube size principally
through the activation (phosphorylation) of the transcription
factor, STAT3, which directly inhibits MyoD synthesis translat-
ing into reduction of MyHC-II gene (Myh2) expression.29,32
TNFα ± IFNγ also deactivates the anabolic pathway,
Akt/mTOR, to reduce sarcomeric protein synthesis.33
Treatment of C2C12 myotubes with TNFα ± IFNγ for 72 h
resulted in the reduction of myotube diameters (Figure 4A),
increased expression of RAGE, S100B, and HMGB1, and mas-
sive S100B and HMGB1 release (Figure 4B,C and Figure S6A).
Thus, in accordance with data obtained in vivo (Figure 1)
atrophying stimuli up-regulate RAGE in myotubes. A blockade
of RAGE activity using a RAGE neutralizing antibody (Ab-
RAGE) strongly prevented TNFα ± IFNγ-induced reduction of
myotube size, as indicated by unchanged myotube diameters
(Figure 4A) and unchanged levels of MyHC-II protein and
mRNA compared with untreated myotubes (Figure 4D,E).
Accordingly and consistent with in vivo data (Figure 3 and
Figures S3,S5), primary Ager/ myotubes were resistant to
TNFα ± IFNγ-induced atrophy (Figure 4F and Figure S6D,E).
Moreover, the pre-treatment of C2C12 myotubes with an
S100B neutralizing antibody (Ab-S100B) together with the
specific HMGB1 inhibitor, glycyrrhizin, completely protected
myotubes from TNFα ± IFNγ-induced atrophy and MyHC-II
breakdown (Figure S6B,C). Thus, S100B- and/or HMGB1-
activated RAGE signalling is required for induction of the atro-
phy programme in response to cytokine treatment.
Treatment of C2C12 myotubes with TNFα alone induced (i)
a biphasic up-regulation of RAGE and myogenin mRNA and
protein (Figure 4G and Figure S7A); (ii) downregulation of
MyoD (Figure S7A), complying with the observed reduction
of Myh2 transcription (Figure 4E); (iii) up-regulation of Myog
and Fbxo32, which were maximal at 2 h and preceded by
Ager up-regulation (maximal at 15 min) (Figure 4G); (iv) un-
changed levels of Trim63 until 6 h (Figure 4G); and (v) deacti-
vation of Akt, activation p38 MAPK and NF-κB(p65), and
unchanged ERK1/2 phosphorylation levels (Figure 4H and Fig-
ure S7A). The activation of p38 MAPK and NF-κB(p65)
showed a main peak at 10–15 min and a further increase
around 6 h concomitantly with the lowest phosphorylation
extent of Akt (Figure S7A). Importantly, pharmacological inhi-
bition of p38 MAPK by SB203580 resulted in inability of TNFα
to reduce myotube diameter, degrade MyoD, and up-
regulate Myog and Fbxo32 (Figure S7D-F). In contrast,
myotubes pre-treated with the NF-κB chemical inhibitor,
BAY11-7082, still increased Myog and Fbxo32 levels in re-
sponse to TNFα (Figure S7G), suggesting that myogenin-
induced UPS activation is independent of NF-κB activity and
dependent on p38 MAPK. However, MyoD degradation and
the consequent reduction of myotube diameter upon treat-
ment with TNFα was also dependent on NF-κB activation (Fig-
ure S7D,H). Interestingly, SB203580 completely prevented
the increase in TNFα-induced Ager transcription in C2C12
myotubes, whereas BAY11–7082 was without effects (Figure
S7F,G). Thus, p38 MAPK is a major inducer of RAGE expres-
sion in cytokine-dependent muscle atrophy.
In the presence of Ab-RAGE, TNFα was unable to (i) deac-
tivate Akt and activate p38 MAPK (Figure 4H); (ii) up-regulate
myogenin (mRNA and protein) and Fbxo32 (Figure 4I,J); and
(iii) reduce MyoD levels (Figure 4K). RAGE blockade did not
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Figure 4 Receptor for advanced glycation end-products (RAGE) signalling is required for tumour necrosis factor (TNF)α ± interferon (IFN)γ-induced re-
duction of myotube size. (A–E, G–M) Myotubes obtained by culturing C2C12 myoblasts in differentiation medium (DM) for 4 days were added with
TNFα (20 ng/ml) ± IFNγ (100 U/ml) in absence and presence of a RAGE blocking antibody (Ab-RAGE) (10 μg/ml) for the indicated time. (A) Myosin heavy
chain (MyHC)-II expression was analysed by immunofluorescence (IF). Reported are the percentages of myotubes diameters compared with control.
(B) RAGE expression was evaluated by western blot (WB). (C) The conditioned media of TNFα ± IFNγ-treated myotubes were processed for detection of
released S100 calcium-binding protein B (S100B) and high mobility group box 1 (HMGB1) by WB. The tubulin is relative to cell lysates from which the
media are derived. (D,E) levels of MyHC-II protein and messenger RNA (mRNA) were evaluated by WB (D) and real-time PCR (E). (F) Myotubes obtained
from primary myoblasts from wild type (WT) or Ager/ mice were treated with TNFα ± IFNγ to analyse MyHC-II expression. (G) Levels of Ager, Myog,
Fbxo32, and Trim63 were analysed by real-time PCR. (H) Total and phosphorylated protein kinase B (Akt), p38 mitogen-activated protein kinase
(MAPK), and p65 levels were analysed by western blot (WB). (I) Levels of Myog and Fbxo32 were evaluated by real-time PCR. (J,K) Myogenin (J)
and myoblast determination protein 1 (MyoD) (K) expression was evaluated by WB. (L,M) the expression and localization of total and phosphorylated
signal transducer and activator of transcription 3 (STAT3) were studied by WB (L) and IF (M). Reported are the relative densities with respect to tubulin
or total form of phosphorylated protein (D,H,J–L). Results are means ± standard error of the mean (SEM) (A,F) or standard deviation (SD) (D,E,G–L).
Statistical analysis was conducted using the two-tailed t-test.
*
P < 0.05,
**
P < 0.01, and ***P<0.001, significantly different from internal control.
#P < 0.05 and ##P < 0.01, significantly different. Scale bars (A,F,M), 100 μm. See also Figure S6,7.
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affect significantly the NF-κB activation state (Figure 4H).
Treatment of C2C12 myotubes with TNFα/IFNγ caused similar
effects to those observed with TNFα alone in terms of
myogenin and RAGE levels (Figure S7B,C) and activation ex-
tent of p38 MAPK, NF-κB(p65), Akt, and ERK1/2 (Figure 4H
and Figure S7C).
Yet, different from TNFα, TNFα/IFNγ treatment did not sig-
nificantly affect atrogenes’ expression (Figure S7B). After
TNFα/IFNγ treatment, RAGE up-regulation preceded STAT3
phosphorylation, with a maximum extent at 30 min, and
pho-STAT3 translocation to myonuclei leading to MyoD deg-
radation (Figure 4L,M and Figure S7C). The atrophying effects
of TNFα/IFNγ were unaltered by the presence of SB203580
and/or BAY11–7082 (data not shown), in accordance with
the major role of STAT3 in the TNFα/IFNγ-induced muscle
wasting.29 Instead, in the presence of Ab-RAGE, TNFα/IFNγ
were unable to (i) deactivate Akt and activate p38MAPK (Fig-
ure 4H); (ii) efficiently phosphorylate NF-κB(p65) (Figure 4H);
(iii) activate STAT3 and its translocation to myonuclei (Figure
4L,M); and (iv) induce MyoD degradation (Figure 4K). TNFα or
TNFα/IFNγ did not alter Myog expression and pho-p38 MAPK
and MyoD levels and only slightly induced Fboxo32 in Ager/
 myotubes (Figure S6D,E). Thus, RAGE signalling is required
for muscle protein degradation induced by both p38
MAPK/myogenin-activated UPS, despite the significant phos-
phorylation of NF-κB, and STAT3-dependent MyoD
degradation.
To confirm these effects in vivo, GC muscles of WT mice
were injected with TNFα/IFNγ for three consecutive days.
We found (i) reduced Myh2 levels; (ii) increased Ager,
S100b, and Hmgb1 levels; (iii) re-expression of RAGE in
atrogin-1+ve myofibers; and (iv) massive release of S100B
and HMGB1, compared with vehicle-injected muscles (Figure
S8A-D). CSA analysis showed a marked shift towards lower
values in muscles treated with TNFα/IFNγ compared with
control muscles, with a significant decrease in myofiber diam-
eter consistent with cytokine-induced muscle atrophy (Figure
S8E, left panel). Injection of Ager/ GC muscles with
TNFα/IFNγ did not significantly change the myofiber distribu-
tion compared with vehicle-injected muscles, despite a slight
increase in the percentage of thin myofibers (Figure S8E, right
panel). Thus, absence of RAGE prevents the atrophying effect
of TNFα/IFNγ in vivo.
Dual trophic and atrophying effect of RAGE
signalling in myotubes in the absence of cytokines
Treatment of C2C12 myotubes with Ab-RAGE in the absence
of cytokines resulted in dose-dependent decrease in myotube
size, MyHC-II mRNA and protein levels, reduced activation of
Akt and enhanced activation of p38 MAPK and NF-κB(p65),
and increased myogenin and Fbxo32 and Trim63 levels (Fig-
ure S6F–J). Reduced amounts of MyHC-II were also found
following treatment of C2C12 myotubes with Ab-S100B or
glycyrrhizin to neutralize S100B and HMGB1, respectively
(Figure S6K). Thus, the physiological activity of RAGE
sustained by low levels of its ligands, S100B and HMGB1, ap-
pears to be necessary for myotube trophism in normal
conditions.
Administration of TNFα ± IFNγ to Ab-RAGE-treated
myotubes caused no major changes compared to untreated
controls (Figure 4A), which contrasts with the results obtained
using Ager/myotubes (Figure 4F). Interestingly, administra-
tion of TNFα to C2C12myotubes treated with a higher (50 μg/
ml) dose of Ab-RAGE did reduce their size relative to untreated
controls (Figure S6L). This suggested that while neutralizing
RAGE in control C2C12 myotubes, the Ab-RAGE dose (10 μg/
ml) used in the experiment in Figure 4A did not completely
block RAGE in cytokine-treated myotubes likely because of
the cytokine-induced overexpression of RAGE (Figure 4B,G)
and enhanced release of the RAGE activators, S100B and
HMGB1 (Figure 4C). Thus, the paradoxical effect of atrophying
stimuli in the presence of Ab-RAGE in C2C12myotubes (Figure
4A) might be explained by an uncomplete inhibition of RAGE
activity obtained with the used dose of Ab-RAGE. Combined
together, the results in Figures 4A and S6L suggested that re-
duction of RAGE activity in the presence of TNFα ± IFNγmight
be beneficial to myotubes, the residual RAGE activity likely
exerting trophic effects. Consistently, up to a dose of
200 ng/ml, S100B exerted trophic effects on C2C12myotubes
in standard culture conditions as evidenced by the increased
levels of MyHC-II (Figure 5A). However, at doses ≥2 μg/ml,
S100B exerted the opposite effect, strongly reducing myotube
diameter and Myh2, MyHC-II, and MyoD levels (Figure 5A–D)
in concomitance with increased Ager expression (Figure 5E).
Similar to high S100B, relatively high doses (≥1 μg/ml) of
HMGB1 strongly reduced MyHC-II levels and myotube diame-
ters (Figure 5A,B), with lower doses resulting in no significant
effects (data not shown).
While HMGB1 induced degradation of muscle proteins in
cancer conditions by the activation of the autophagy sys-
tem,34 the role of S100B in muscle wasting remained
uninvestigated. We found that high S100B doses reduced
pho-Akt levels, robustly increased pho-p38 MAPK, pho-
STAT3, and myogenin levels (Figure 5F), induced pho-STAT3
nuclear translocation (Figure 5H), and up-regulated Fboxo32
and Trim63 levels (Figure 5G) in C2C12myotubes, with no sig-
nificant effects on NF-κB(p65) and ERK1/2 phosphorylation
levels (data not shown). Notably, doses of S100B causing re-
duction of myotube size up-regulated Ager expression with
maximum effect at 30 min in coincidence with the maximal
expression of atrogenes (Figure 5E,G) and preceding the max-
imum accumulation of RAGE protein (at 1 h) (Figure 5F).
Thus, high S100B induces muscle protein degradation per se
as opposed to its trophic effects at low doses.
RAGE and p38 MAPK appeared to mediate the effects of
high S100B in C2C12 myotubes because Ab-RAGE and
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Figure 5 Dual trophic and atrophying effect of receptor for advanced glycation end-products (RAGE) signalling in myotubes in the absence of cyto-
kines. (A–N) C2C12 myotubes were cultured with S100 calcium-binding protein B (S100B) (0–20 μg/ml) in the absence or presence of either Ab-RAGE
or SB203580, or with high mobility group box 1 (HMGB1) (0–30 μg/ml). Levels of MyHC-II was evaluated by western blot (WB) (A), immunofluores-
cence (IF) (B) and real-time PCR (C). Reported are the percentages of myotubes diameters relative to control (B). (D,E) myoblast determination protein
1 (MyoD) (D) and Ager (E) expression was analysed by western blot (WB) and real-time PCR, respectively. (F) Levels of RAGE, myogenin, MyoD, and
total and phosphorylated protein kinase B (Akt), p38 mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription
3 (STAT3) were evaluated by WB. (G) Levels of Ager, Myog, Fbxo32, and Trim63 were analysed by real-time PCR. (H) the localization of pho-STAT3
was evaluated by IF. (I) The expression of myosin heavy chain (MyHC)-II was evaluated by WB, and the percentage of myotubes diameters respect
to control was determined. (J,K) Levels of Ager (J) and Myog, Fbxo32, and Trim63 (J,K) were analysed by real-time PCR. (L-N) Levels of MyoD protein
(L,M) were analysed by WB, and total and phosphorylated STAT3 levels were analysed by WB (N). (O,P) Gastrocnemius muscles of WT and Ager/
mice (n = 5 each group) were injected daily for three consecutive days with S100B (50 ng/muscle) or vehicle [phosphate-buffered saline(PBS)] and
analysed for the expression of Ager (O), and Fbxo32 and Myog (P) by real-time PCR. Results are means ± standard error of the mean (B,I) or standard
deviation (C,E,G,J–P). Statistical analysis was conducted using the two-tailed t-test. *P < 0.05 and **P < 0.01, significantly different from internal con-
trol.
#
P < 0.05 and
##
P < 0.01, significantly different. Scale bars (B,H,I), 100 μm.
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SB203580 completely abolished high S100B’s ability to induce
atrophy, as assessed by measurement of myotube diameters
(Figure 5I),Myog and atrogenes levels (Figure 5J,K), andMyoD
amounts (Figure 5L,M). Moreover, Ab-RAGE completely
abolished high S100B’s effects on STAT3 phosphorylation
and nuclear translocation (Figure 5H,N). Interestingly, as in
the case of TNFα (Figure S7F), high S100Bwas unable to induce
Ager up-regulation in the presence of SB203580 (Figure 5J),
suggesting the involvement of a common p38 MAPK-
dependent mechanism. In accordance with these in vitro data,
local injection of high S100B for two consecutive days resulted
in up-regulation of Ager, Myog, and Fbxo32 levels in GC mus-
cles of WT but not Ager/ mice (Figure 5O,P). Collectively,
these results suggested that overexpression and hyper-
stimulation of RAGE induced by high S100B might trigger mus-
cle atrophy via a p38 MAPK/myogenin axis and STAT3-
dependent MyoD degradation, possibly amplifying the activity
of cachexia-inducing cytokines.
Reducing RAGE activity prevents reduction of
myotube size induced by tumour-derived factors
Administration of LLC- or C26-CM to C2C12 myotubes reca-
pitulated the muscle protein catabolism seen in tumour-
bearing mice through UPS activation via p38 MAPK.35 C2C12
myotubes treated with LLC- or C26-CM showed rapid up-
regulation of Ager (Figure 6A) and S100b with unaffected
levels of Hmgb1 (Figure S9A). Treatment with Ab-RAGE re-
duced tumour cell-derived factors’ ability to decrease
myotube diameter (Figure 6B), up-regulate Trim63 (Figure
6C), and increase pho-p38 MAPK levels (Figure 6D). Thus, in-
hibition of RAGE activity might reduce the atrophying effects
of tumour-derived factors in muscles.
In vitro cultured LLC cells and LLC tumour masses developed
in WT or Ager/mice expressed RAGE (Figure S9B,C). MAC3+ve
tumour-associated macrophages (TAMs) also expressed RAGE in
WT mice (Figure S9C). Interestingly, LLC-TM reduced C2C12
myotube diameter when derived from tumour developed in
WT mice and isolated at 15 dpi but not when derived from
Ager/ mice until 35 dpi (Figure 6E). Thus, RAGE expressed
in non-tumour cells sustained the secretion of cachexia-
promoting factors from tumour masses. Interestingly, tumours
developed in Ager/ mice released smaller amounts of
S100B, but not HMGB1, at 25 dpi compared with those derived
fromWT mice (Figure 6F), suggesting that the presence of RAGE
influences the secretion of S100B from tumour masses.
Discussion
The results described herein point to a previously unravelled
role of RAGE as a major player underpinning all hallmarks of
cachexia under cancer conditions, that is, loss of body weight
and muscle mass, systemic inflammation, and release of
tumour-derived cachexia-inducing factors.
RAGE, which is absent in adult healthy muscle,21 is re-
expressed in atrophying myofibers via p38 MAPK under the ac-
tion of proinflammatory cytokines and elevated serum levels of
S100B and HMGB1, released from tumour cells. The re-
expression of RAGE in myofibers precedes the loss of body
weight and muscle mass and strength in tumour-bearing mice
and is concomitant with the activation of muscle proteolytic
UPS and the up-regulation of myogenin, suggesting a crucial role
in the onset of muscle wasting process. Indeed, in cancer condi-
tions RAGE chronically activated by its ligands induces the acti-
vation of multiple catabolic pathways, that is, p38 MAPK and
STAT3, and the deactivation of the anabolic kinase, Akt, leading
at the same time to hampered MyHC synthesis and increased
muscle protein degradation.
We show that myogenin is re-expressed in the nuclei of
atrophic myofibers, and we identified for the first time RAGE
as a receptor able to induce myogenin expression in cachectic
muscles. Muscle regeneration is highly compromised in ca-
chexia conditions, and proliferating Pax7+ve cells are unable
to terminally differentiate (and to express myogenin) and
fuse into myofibers because they are prevented by tumour-
derived factors influencing the muscle microenvironment. In-
deed, muscles of cachectic mice typically do not show
centrally-nucleated myofibers.27,28 Accordingly, we found
higher percentages of PAX7+ve/ki67+ve mononuclear cells in
muscles of LLC-Ager/ vs LLC-WT mice (18.3 vs. 10.2%, re-
spectively), and absence of myogenin+ve mononuclear cells
in both LLC-WT and LLC-Ager/ muscles at 25 dpi (data
not shown). Thus, the myogenin+ve nuclei observed in
wasting conditions (Figures 3D and S5E) are reasonably
myonuclei (as identified by dystrophin localization) rather
than nuclei of fused myogenin+ve precursor cells, and the re-
duced expression of myogenin in LLC-Ager/ muscles is in-
dependent of myogenic stimuli. We speculate that the
RAGE/p38 MAPK/myogenin/atrogin-1 axis might establish a
common finely regulated loop in physiological and pathologi-
cal settings leading to appropriate building of muscle mass or
excessive muscle protein degradation, respectively. Indeed,
(i) myogenin is required for the activation of atrogin-1, which
is necessary to limit the levels of myogenic transcription fac-
tors, including myogenin itself, during both myogenesis and
muscle wasting conditions (i.e. denervation, spinal muscular
atrophy, and starvation)8,9,26,36,37; (ii) myogenin expression
is regulated by RAGE signalling, and myogenin is at the same
time a positive regulator of RAGE and atrogin-112,16,38; and
(iii) chronic expression of RAGE in adult myofibers occurs in
diabetes, ageing, and obesity, that is, pathological conditions
characterized by muscle atrophy.12 Thus, RAGE, like other
signalling pathways, might play distinct roles in muscle
regeneration and in the balance of protein synthesis and
degradation.28
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Figure 6 Reducing receptor for advanced glycation end-products (RAGE) activity prevents reduction of myotube size induced by tumour-derived fac-
tors and reduces the release of cachexia-inducing factors from Lewis lung carcinoma (LLC) tumour. (A–D) C2C12 myotubes cultured with conditioned
medium derived from LLC cells (LLC-CM) or C26 cells (C26-CM) in the absence or presence of Ab-RAGE (10 μg/ml). (A) Ager levels were analysed by
real-time PCR. (B) myosin heavy chain (MyHC)-II expression was analysed by immunofluorescence (IF), and the percent changes in myotube diameter
relative to the control were determined. Trim63 and total and phosphorylated p38 mitogen-activated protein kinase (MAPK) were analysed by real-
time PCR (C) and western blot (WB) (D), respectively. (E) C2C12 myotubes were cultured with medium conditioned by LLC masses (LLC-TM) derived
from wild type (WT) or Ager/ (n = 5 each group) at various day post injection. Measurements of myotube diameters after MyHC-II immunocyto-
chemistry (ICC) analysis are shown as percentage change relative to control. (F) LLC-TM derived from WT or Ager/ were analysed for S100 cal-
cium-binding protein B (S100B) and high mobility group box 1 (HMGB1) content by WB. GAPDH is relative to tumour lysates from which the media
are derived. Results are means ± standard error of the mean (B,E) or standard deviation (A,C,D). Statistical analysis was conducted using the two-tailed
t-test.
*
P < 0.05 and
**
P < 0.01, significantly different from internal control.
#
P < 0.05 and
##
P < 0.01, significantly different. Scale bars (B,E), 100 μm.
See also Figure S9.
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We also demonstrate that RAGE is determinant in the mus-
cle atrophy induced by proinflammatory cytokines and/or
tumour-derived cachexia-inducing factors. Blocking RAGE
results in inability of TNFα, TNFα/IFNγ, and tumour-CM to ac-
tivate the signalling pathways leading to muscle protein
degradation.
Incidentally, our results shed light on the controversial
mechanism used by TNFα to induce atrophy in vitro. TNFα re-
duces MyHC levels by inducing the degradation of MyoD,
which is known to drive the transcription of structural pro-
teins including MyHC.37 MyoD degradation requires two nec-
essaries but not sufficient independent mechanisms, that is,
the recruitment of a p38 MAPK/myogenin/atrogin-1/UPS axis
and the activation of NF-κB signalling without the involve-
ment of UPS. The fact that Trim63, which is able to directly
degrade MyHC,37 is not upregulated by TNFα supports a ma-
jor role of atrogin-1-dependent MyoD degradation in induc-
ing myotube atrophy.
The preservation of muscle mass and a reduced occur-
rence of cancer metastasis have been correlated to survival
in human cachectic patients.4,39 Thus, the reduced presence
of lung metastases together with the reduced muscle and
body loss at 25 dpi might explain the dramatically high
(80%) survival rate observed in LLC-Ager/ mice at the day
of euthanasia (40 dpi) compared with LLC-WT mice (no survi-
vors). The higher survival rate of LLC-Ager/ mice at 40 dpi
despite a dramatic loss of muscle mass and the presence of
a high number of lung metastases, point to a major role of
the reduction of the inflammatory state in accordance with
previous work.40,41 Indeed, survivor LLC-Ager/ mice at 40
dpi showed even lower serum levels of TNFα and IFNγ than
cachectic LLC-WT mice at 25 dpi, suggesting that these two
cytokines are pivotal in determining an unfavourable progno-
sis. Interestingly, survivor LLC-Ager/ mice showed lower
levels of the anti-inflammatory cytokine, IL-10. This might re-
flect a reduced inflammatory state and/or a reduced release
of IL-10 by RAGE-negative TAMs in LLC masses leading to in-
creased survival, as reported in other tumour types.42
In certain types of cancer, RAGE and its ligands promote
spleen accumulation of myeloid-derived suppressor cells,43
which have been strongly implicated in development of can-
cer cachexia, splenomegaly, and poor survival of cancer pa-
tients25 and whose activity has been correlated to serum
levels of IL-3 and IL-17.44 Accordingly, splenomegaly is
delayed, and the morphology of spleen is conserved even at
40 dpi in LLC-Ager/ mice, in concomitance with low serum
levels of IL-3 and IL-17.
We demonstrate that S100B and HMGB1 are able to in-
duce muscle atrophy per se at relatively high doses, behaving
as cachexia-inducing factors, and that S100B and HMGB1 are
massively released from tumour masses. The combination of
elevated serum S100B levels and RAGE overexpression in
muscles, as seen in tumour-bearing mice and cytokine-
induced experimental cachexia, switches the effect of the
S100B-RAGE pair from trophic to atrophying. While released
HMGB1 might likewise contribute to RAGE-induced muscle
atrophy in cancer conditions, HMGB1’s ability to activate
TLR-445,46 limits conclusions about its pro-cachexia effects
via RAGE signalling.
Surprisingly, we found that Ager/ mice show a peculiar
myofiber composition characterized by the persistence of de-
velopmental form of MyHC (dMyHC), a dramatic prevalence
of the slow isoform, MyHC-I, and the almost complete ab-
sence of the fast isoform, MyHC-II, in adult healthy muscles,
although the absence of RAGE does not translate into overt
muscle defects.16 Because dMyHC and MyHC-I precede
MyHC-II during murine muscle development,47 the extremely
low levels of MyHC-II together with the high levels of MyoD
and dMyHC found in Ager/ mice suggest an inability to
achieve complete muscle maturation. The reduced content
of type II myofibers, which are more vulnerable to cancer ca-
chexia,48 might concur to the resistance of Ager/ mice to
tumour-induced atrophy. However, an inverse shift from type
I to type II myofibers occurs in the absence of RAGE in ca-
chectic conditions, which deserves future investigation.
RAGE is a potent inducer of tumour growth and malignant
conversion, migration, and invasion in many cachexia-
inducing cancer types; however, a RAGE tumour-suppressive
function has been reported in other cachexia-inducing can-
cers.11,12,15 Interestingly, (RAGE+ve) LLC tumours developed
in Ager/ mice released smaller amounts of the cachexia-
promoting S100B and were less able to induce reduction of
myotube size compared with LLC tumours developed in WT
mice. Thus, RAGE expression and activity in tumour cells do
not seem to be primarily associated with the tumour’s ability
to induce cachexia; cachexia might be linked to the expres-
sion of RAGE in tumour-associated cells (such as TAMs), as
well as to the presence in the serum of different RAGE ligands
and likely the RAGE antagonist soluble form, sRAGE. Absence
of RAGE in non-tumour cells does not affect the extent of fi-
brotic and necrotic areas over time in LLC tumour masses,
further supporting that the different degree of cachexia of
LLC-WT and LLC-Ager/ mice at 25 dpi is not caused by
different amounts of actively growing cancer cells.
Altogether, our results suggest that targeting RAGE might
represent a promising approach to counteract loss of muscle
mass and strength and prolong survival in cancer patients,
and measuring serum levels of the RAGE ligands, S100B and
HMGB1, in non-cachectic patients might be of prognostic
value toward the future occurrence of cachexia.
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